homepage-top-section

German company MorphoSys has signed a definitive agreement to acquire US-based Constellation Pharmaceuticals for approximately $1.7bn. Under the terms of the agreement, MorphoSys’ wholly-owned subsidiary will begin a

Amgen has signed an agreement with Japanese pharmaceutical firm Kyowa Kirin to jointly develop and commercialise Phase III-ready antibody for treating atopic dermatitis. Discovered by Kyowa Kirin, the

South Korean drug manufacturer Samsung Biologics is planning to expand its portfolio of services by adding a mRNA vaccine drug substance (DS) manufacturing line at its facility in

The European Union (EU) has expanded the conditional marketing authorization (CMA) for Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, to include adolescents aged 12 to 15 years. The authorisation

Prestige Consumer Healthcare has agreed to acquire specialty pharmaceuticals provider Akorn Operating Company’s Consumer Health business for approximately $230m. Under the terms of a definitive agreement signed by

Private equity firm Carlyle Group’s subsidiary Murano Bidco has agreed to acquire British pharmaceutical company Vectura Group for about $1.4bn (£958m). Under the terms of the acquisition, Murano

Biotechnology company Pieris Pharmaceuticals has signed a multi-programme research collaboration and licence agreement with Roche Group subsidiary Genentech. Genentech focuses on discovering and developing medicines for serious and

US-based pharmaceutical company Xeris Pharmaceuticals has agreed to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267m. Strongbridge is a commercial-stage

The Ministry of Health, Labour and Welfare (MHLW) of Japan has granted emergency use authorization for Covid-19 vaccines developed by AstraZeneca and Moderna. AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]), co-invented